Ventilator-associated tracheobronchitis (VAT): questions, answers, and a new paradigm? by Craven, Donald E
Page 1 of 2
(page number not for citation purposes)
Available online http://ccforum.com/content/12/3/157
Abstract
Nosocomial lower respiratory tract infections are a common cause
of morbidity and mortality in intensive care unit (ICU) patients.
Although many studies have investigated the management and
prevention of ventilator-associated pneumonia (VAP), few have
focused on ventilator-associated tracheobronchitis (VAT). In this
issue of Critical Care, Nseir and coworkers present interesting
data from a randomized controlled study of antimicrobial therapy
for VAT. Patients randomly assigned to antibiotic therapy had more
mechanical ventilation-free days (P < 0.001), fewer episodes of
VAP (13% versus 47%; P < 0.001), and a lower ICU mortality rate
(18% versus 47%; P = 0.05) than those without antibiotic therapy.
Although this study has limitations, the data suggest that VAT may
be an important risk factor for VAP or overlap with early VAP. More
importantly, targeted antibiotic therapy for VAT may improve
patient outcomes and become a new paradigm for prevention or
early therapy for VAP.
In this issue of Critical Care, Nseir and coworkers [1] provide
interesting data from a randomized trial of antibiotic therapy
for ventilator-associated tracheobronchitis (VAT). Although
ventilator-associated pneumonia (VAP) has been the major
focus of critical care providers, perhaps our focus should also
include VAT, which may be a precursor to VAP or overlap
with early VAP [1-5]. Understanding VAT may have important
implications for the early diagnosis, therapy, and prevention of
VAP. In comparison with VAP, VAT is plagued by little clinical
data and several questions: How do we define it? How much
does it overlap with VAP? What level of bacteria in
endotracheal aspirates is diagnostic? When is antibiotic
therapy indicated and for how long [5]?
Most bacteria enter the lower respiratory tract by leakage of
bacteria and oropharyngeal secretions around the endo-
tracheal tube cuff, resulting in colonization, VAT, or VAP [2].
Furthermore, the primary exit route for bacteria out of the
lower respiratory tract is impeded by the endotracheal tube,
patient sedation, and a reliance on mechanical suctioning
rather than spontaneous coughing. The lower respiratory
tract in the ventilated patient is a continuous ‘battleground’
between the numbers, types, and virulence of the incoming
bacteria versus the lung’s incredible mechanical, cellular, and
humoral defenses. The outcome for each patient is either
lower airway colonization or shades of grey from VAT to VAP.
Diagnoses of both VAT and VAP rely on clinical and systemic
signs of infection (fever, leukocytosis, reduced oxygenation)
plus purulent sputum with high concentrations of bacteria
(≥105-6 colony-forming units [cfu]/mL) in the endotracheal
aspirate. Diagnoses of VAP rely on distal samples of bacteria
obtained from bronchoscopic and non-bronchoalveolar
lavage (≥104 cfu/mL) [2] or protected specimen brush (PSB)
(≥103 cfu/mL). Definitions of VAT and VAP have been based
on different sampling techniques and microbiologic
thresholds, which may make discrimination between VAT and
VAP difficult. Although VAP requires evidence of a new and
persistent infiltrate on a chest x-ray, the sensitivity and
specificity of x-rays are variable and, though improved with
computerized tomographic scans, still have limitations,
especially in patients with severe congestive heart failure or
adult respiratory distress syndrome.
For VAP, and probably VAT, early appropriate antibiotic
therapy improves patient outcomes [1,2]. Nseir and co-
workers [4] reported an observational cohort of medical and
surgical intensive care unit (ICU) patients who had a 10.6%
incidence of VAT. VAT was associated with an increased
length of stay (LOS) in the ICU and more mechanical
ventilator days, but those receiving antimicrobial therapy had
a trend toward decreased LOS, fewer mechanical ventilator
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days, and lower mortality. In a more recent case control study
in ventilated patients with chronic respiratory failure, patients
with VAT had a significantly longer duration of mechanical
ventilation (17 versus 8 days; P < 0.001) and ICU stays (24
versus 12 days; P < 0.001) [6]. Nouria and coworkers [7]
compared the impact of ofloxacin versus placebo in a
randomized trial of mechanically ventilated patients with
chronic lung disease and noted significantly better outcomes
in the ofloxacin group.
A’Court and coworkers [8] studied the natural history of
colonization in mechanically ventilated patients using serial
non-bronchoscopic bronchial lavage with quantitative
cultures collected every 48 hours. These investigators
reported a significant increase in lower respiratory tract
colony counts which started 2 days before the clinical onset
of VAP, which may have represented either VAT or early VAP
not detected by chest x-ray. In this issue, Nseir and
coworkers [1] present interesting data from a small ran-
domized, controlled, multicenter trial of patients with VAT
who were randomly assigned to antibiotic therapy versus no
therapy. VAT was defined as a first episode of fever of greater
than 38°C, purulent sputum production, endotracheal
aspirate having greater than or equal to 106 cfu/mL of a new
pathogen, but no radiographic signs of VAP on a chest x-ray.
Pseudomonas aeruginosa,  Acinetobacter baumannii, and
methicilllin-resistant  Staphylococcus aureus (MRSA) were
the most common pathogens isolated. Results were
presented as intention-to-treat (ITT) and a modified ITT (MITT)
analysis which excluded patients with potential confounders.
In both analyses, the antibiotic-treated group had a significant
decrease in VAP (P < 0.01), more mechanical ventilation-free
days (P < 0.001), and a lower ICU mortality (P < 0.05). These
data of Nseir and coworkers [1] are interesting and provoca-
tive and suggest that VAT caused by these pathogens may
be a marker for patients at high risk for developing VAP and
that early appropriate antibiotic therapy for VAT or pre-
emptive therapy for early VAP may significantly improve
patient outcomes. Study limitations of note include the
following: lack of blinding; low numbers of patients; the study
was stopped before randomization blocks were attained; an
independent blinded committee did not evaluate the
endpoints; and, finally, computer-assisted tomography was
not performed systematically to exclude VAP.
The data of Nseir and coworkers [1] need confirmation but
suggest a new paradigm to assess tracheal colonization,
whether treating VAT or early VAP. Also, treatment of VAT
may reduce lung inflammation, which may translate into
earlier extubation and reduced risk for VAP. Finally, the
presence of high concentrations of a bacterial pathogen in
the endotracheal aspirate may be an important clinical clue
that antibiotic therapy is needed to aid failing host defenses
and reduce patient mortality, morbidity, and health care costs.
The limitations of the study by Nseir and coworkers [1]
underscore the need for larger collaborative national and
international networks to develop well-designed trials, with
independent data analysis and data safety monitoring boards,
that would greatly increase our understanding of disease
pathogenesis, prevention, and treatment. Such a network
could provide a foundation on which to build vitally needed
‘gold standards’ to improve patient care, outcomes, and
prevention of VAP and other health care-associated
infections. Progress usually is based on a series of small
steps, but bigger and better steps are not only possible, but
vitally needed.
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